Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis.

Yuki TahataRyotaro SakamoriKazuki MaesakaAkira DoiRyoko YamadaTakahiro Kodama Hayato HikitaMasanori MiyazakiYasutoshi NozakiAkira KanekoMasahide OshitaSatoshi TanakaKazuho ImanakaNaoki HiramatsuNaoki MorishitaKazuyoshi OhkawaTakayuki YakushijinMitsuru SakakibaraSadaharu IioYoshinori DoiTomohide Tatsuminull AndTetsuo Takehara

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2022)

SOF/VEL therapy may suppress the development of decompensated events and improve the prognosis in decompensated cirrhotic patients; however, the incidence of HCC remains prevalent in these patients irrespective of SOF/VEL therapy. This article is protected by copyright. All rights reserved.

Keyphrases

ejection fraction
hepatitis c virus
heart failure
end stage renal disease
newly diagnosed
peritoneal dialysis
prognostic factors
stem cells
risk factors
mesenchymal stem cells
patient reported outcomes
bone marrow
hiv infected